KALA Kala Pharmaceuticals


Data from SEC filings
Employee count

ESG framework mentions

In last year of SEC filings
Sustainability Accounting Standards Board (SASB)
No mentions
Global Reporting Initiative (GRI)
No mentions
Task Force on Climate-related Financial Disclosures (TCFD)
No mentions
UN Sustainable Development Goals (SDGs)
No mentions

Shareholder alignment

Proxy contests and exempt solicitations in last 3 years

No recent proxy contest or exempt solicitation filings from shareholders.

Vote support at last AGM
At the 2021 Annual Meeting of Stockholders of Kala Pharmaceuticals, Inc. (the “Company”) held on June 17, 2021, the Company’s stockholders voted on the following proposals:

1.The Company’s stockholders elected Messrs. Andrew I. Koven and Gregory D. Perry as Class I directors, each to serve for a three-year term expiring at the 2024 Annual Meeting of Stockholders and until his successor has been duly elected and qualified. The results of the stockholders’ vote with respect to the election of such Class I directors were as follows:

Votes For Votes
Andrew I. Koven26,102,3456,611,47913,245,295
Gregory D. Perry27,351,1575,362,66713,245,295

2.The Company’s stockholders ratified the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2021. The results of the stockholders’ vote with respect to such ratification were as follows:

Votes For Votes Against Votes Abstaining Broker Non-